Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 0: clinchem.2005.060103v1, 2006; 10.1373/clinchem.2005.060103
This Article
Right arrow Full Text (PDF)
Right arrow 060103.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2005.060103v1
52/6/1196    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Persoon, A. C.M.
Right arrow Articles by van den Ouweland, J. M.W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Persoon, A. C.M.
Right arrow Articles by van den Ouweland, J. M.W.

Received on ,
Accepted on ,

Technical Briefs

Thyroglobulin (Tg) Recovery Testing with Quantitative Tg Antibody Measurement for Determining Interference in Serum Tg Assays in Differentiated Thyroid Carcinoma

Adrienne C.M. Persoon 1, Thera P. Links 1, Juergen Wilde 2, Wim J. Sluiter 1, Bruce H.R. Wolffenbuttel 1, Johannes M.W. van den Ouweland 3*

1 Department of Endocrinology, University Medical Centre Groningen, Groningen, The Netherlands
2 R-biopharm, Darmstadt, Germany
3 Canisius-Wilhelmina Medical Centre, Department of Clinical Chemistry, Nijmegen, The Netherlands

* To whom correspondence should be addressed. E-mail: j.v.d.ouweland{at}cwz.nl.

Background: Thyroglobulin (Tg) measurements are complicated by interference from Tg autoantibodies (TgAbs) or heterophilic antibodies (HAMAs). We used a new automated immunochemiluminometric assay (ICMA) with Tg recovery (TgR) on the Nichols Advantage® platform to reassess the clinical utility of recovery testing in detecting interference in serum Tg measurement in patients with differentiated thyroid carcinoma.

Methods: We used 2 TgAb methods to detect Tg measurement interference with TgR and quantitative TgAb measurement in sera from 127 patients. In a limited number of samples, we used an RIA as comparison method because it appeared to be minimally affected by TgAb.

Results: Prevalence of TgAbs was 13% (17 of 127) in either 1 or both TgAb assays. A compromised TgR (<70%) corresponded with TgAb positivity in either TgAb assay for 10 of 11 samples (91%), whereas a normal TgR (≥70%) corresponded with TgAb negativity in both assays for 95 of 101 samples (94%). In 6 TgAb-positive sera with TgR within the reference interval, there were no discrepancies between RIA and ICMA results. We obtained discordant RIA and ICMA results for 6 of 9 TgAb-positive sera with decreased TgR. In 1 TgAb-negative sample, the Tg result was falsely increased from interference by HAMAs, as shown by an overrecovery of 126%.

Conclusions: The Nichols Advantage TgR assay is a valuable complementary method to overcome the technical problem interference by TgAbs or HAMAs in TgAb assays. Further studies are needed to confirm the potential added value of this TgR assay.


eLetters:

Read all eLetters

How thyroglobulin recovery test really adds to anti-thyroglobulin antibodies quantitative assay whe
Luca Giovanella, et al.
Clinical Chemistry Online, 7 Nov 2006 [Full text]
TgR testing has complementary value to quantitative TgAb measurement in selected cases.
Adrienne C. M. Persoon, et al.
Clinical Chemistry Online, 28 Dec 2006 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the American Association for Clinical Chemistry.